SYNTA PHARMA.CORP mit STA-4783 - 500 Beiträge pro Seite
eröffnet am 04.10.07 10:49:07 von
neuester Beitrag 04.10.07 22:27:16 von
neuester Beitrag 04.10.07 22:27:16 von
Beiträge: 2
ID: 1.133.583
ID: 1.133.583
Aufrufe heute: 0
Gesamt: 1.022
Gesamt: 1.022
Aktive User: 0
ISIN: US5588681057 · WKN: A2APCZ · Symbol: MDGL
191,18
USD
-1,65 %
-3,20 USD
Letzter Kurs 00:17:06 Nasdaq
Neuigkeiten
24.04.24 · globenewswire |
23.04.24 · globenewswire |
16.04.24 · globenewswire |
09.04.24 · globenewswire |
03.04.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
Wertpapier | Kurs | Perf. % |
---|---|---|
1,3254 | +82,86 | |
0,6500 | +25,75 | |
6,0000 | +25,00 | |
56,69 | +20,00 | |
0,6400 | +18,52 |
Wertpapier | Kurs | Perf. % |
---|---|---|
8,5000 | -15,00 | |
0,7300 | -18,59 | |
92,06 | -19,84 | |
2,7280 | -29,14 | |
1,4500 | -64,37 |
Ein Investment das sich lohnen könnte.....
STA-4783 is the first drug in over 30 years to demonstrate an improvement in progression free survival in a double-blind, randomized, controlled, multi-center clinical trial in metastatic melanoma," said Dr. O'Day. "In a disease where there are so few treatment options for patients, it is vitally important to continue the development of new therapeutics such as STA-4783."
Dr. O'Day was the lead investigator on the Phase 2b trial of 81 patients with Stage IV melanoma, and will be the North American lead investigator for the Phase 3 trial of STA-4783. Synta has announced that it plans to initiate an international Phase 3 clinical trial to investigate STA-4783 as a first-line therapy for patients with metastatic melanoma in the third quarter of 2007.
STA-4783 is a novel, injectable, small molecule investigational drug candidate that induces a potent oxidative stress response in cancer cells, driving programmed cell death and enhancing the activity of anti-cancer agents that act through the mitochondrial apoptosis pathway, including paclitaxel. In November 2006, Synta received Fast Track designation from the FDA for the development of STA-4783 in metastatic melanoma.
Based on the broad-acting potential of its novel mechanism of action and the activity seen in laboratory experiments in other cancer types, Synta plans to investigate the use of STA-4783 in additional cancers and in combination with other agents, including announcing one or more Phase 2 studies in other cancer indications later in the year.
STA-4783 is the first drug in over 30 years to demonstrate an improvement in progression free survival in a double-blind, randomized, controlled, multi-center clinical trial in metastatic melanoma," said Dr. O'Day. "In a disease where there are so few treatment options for patients, it is vitally important to continue the development of new therapeutics such as STA-4783."
Dr. O'Day was the lead investigator on the Phase 2b trial of 81 patients with Stage IV melanoma, and will be the North American lead investigator for the Phase 3 trial of STA-4783. Synta has announced that it plans to initiate an international Phase 3 clinical trial to investigate STA-4783 as a first-line therapy for patients with metastatic melanoma in the third quarter of 2007.
STA-4783 is a novel, injectable, small molecule investigational drug candidate that induces a potent oxidative stress response in cancer cells, driving programmed cell death and enhancing the activity of anti-cancer agents that act through the mitochondrial apoptosis pathway, including paclitaxel. In November 2006, Synta received Fast Track designation from the FDA for the development of STA-4783 in metastatic melanoma.
Based on the broad-acting potential of its novel mechanism of action and the activity seen in laboratory experiments in other cancer types, Synta plans to investigate the use of STA-4783 in additional cancers and in combination with other agents, including announcing one or more Phase 2 studies in other cancer indications later in the year.
Noch einmal heute Abend +11,69 % das Tempo nimmt rasant an Tempo nach oben zu!
So machen Biotechs Spaß...........
So machen Biotechs Spaß...........
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
+0,83 | |
-0,13 | |
+2,14 | |
+2,53 | |
-0,23 | |
+8,36 | |
+1,18 | |
+2,85 | |
+3,73 | |
-0,12 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
215 | ||
90 | ||
78 | ||
58 | ||
55 | ||
35 | ||
34 | ||
29 | ||
27 | ||
25 |
24.04.24 · globenewswire · Madrigal Pharmaceuticals |
23.04.24 · globenewswire · Madrigal Pharmaceuticals |
16.04.24 · globenewswire · Madrigal Pharmaceuticals |
09.04.24 · globenewswire · Madrigal Pharmaceuticals |
03.04.24 · globenewswire · Madrigal Pharmaceuticals |
19.03.24 · globenewswire · Madrigal Pharmaceuticals |
18.03.24 · globenewswire · Madrigal Pharmaceuticals |
15.03.24 · Sharedeals · Madrigal Pharmaceuticals |
14.03.24 · globenewswire · Madrigal Pharmaceuticals |
06.03.24 · globenewswire · Madrigal Pharmaceuticals |
Zeit | Titel |
---|---|
20.03.24 |